Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q4 FY26 results · Jan–Mar 2026
Caplin Point Laboratories reported revenue from operations of ₹600.16 crore (up 19.4% from Q4 FY25) and net profit of ₹172.88 crore (up 19.0% from Q4 FY25) for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 600.16 | 502.45 | +19.4% | 542.77 | +10.6% |
| Other income | 28.36 | 25.74 | +10.2% | 33.68 | −15.8% |
| Total income | 628.52 | 528.19 | +19.0% | 576.45 | +9.0% |
| Profit before tax | 213.44 | 176.59 | +20.9% | 203.91 | +4.7% |
| Net profit for the period | 172.88 | 145.28 | +19.0% | 165.86 | +4.2% |
| Attributable to shareholders of the company | 170.11 | 140.82 | +20.8% | 163.88 | +3.8% |
| EPS, basic (₹) | 22.38 | 18.75 | +19.4% | 21.56 | +3.8% |
| Net margin (%) | 28.8 | 28.9 | 30.6 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 191.36 | 173.61 | +10.2% | 189.22 | +1.1% |
| Other income | 61.08 | 41.25 | +48.1% | 31.73 | +92.5% |
| Total income | 252.44 | 214.86 | +17.5% | 220.95 | +14.3% |
| Profit before tax | 137.72 | 110.16 | +25.0% | 117.01 | +17.7% |
| Net profit for the period | 109.50 | 86.50 | +26.6% | 87.28 | +25.5% |
| EPS, basic (₹) | 15.89 | 11.37 | +39.8% | 11.49 | +38.3% |
| Net margin (%) | 57.2 | 49.8 | 46.1 |
Consolidated
- Filed with BSE
- 14 May 2026, 21:23 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 May 2026, 21:23 IST
- Board meeting
- 14 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Audited
- Source
- XBRL filing on BSE